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a b  s  t  r a  c t
We  investigate  the  extent  to  which  healthcare service utilisation  and  costs can  be predicted
from  biomarkers, using  the UK  Understanding  Society  panel.  We  use  a sample  of 2314
adults  who  reported no history of diagnosed  long-lasting  health conditions  at baseline
(2010/11), when biomarkers  were collected.  Five  years  later, their  GP,  outpatient  (OP) and
inpatient  (IP) utilisation was observed.  We develop  an econometric  technique  for  count
data  observed  within  ranges  and  a method of combining administrative reference cost  data
with  the  survey data without exact individual-level  matching.  Our  composite  biomarker
index  (allostatic  load)  is a  powerful  predictor  of costs:  for  those with  a baseline  allostatic
load of  at  least  one  standard  deviation (1-s.d.) above  mean,  a 1-s.d. reduction reduces  GP,
OP  and IP costs by  around  18%.
© 2020 The Authors.  Published by  Elsevier B.V.  This  is  an  open  access article  under  the  CC
BY license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Health care costs have risen faster than the rate of eco-
nomic growth in all OECD countries and this is  projected
to continue as a  result of new medical technology, rising
expectations and the increasing needs of the ageing popu-
lation (OECD, 2015).  In Britain, about 10% of GDP is  spent on
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the National Health Service (NHS), which is  broadly in  line
with other European counties. That proportion has doubled
since the establishment of the NHS in  1948 (Charlesworth
and Bloor, 2018). In this policy setting, it is important for
policymakers to  be able to identify the sections of the popu-
lation where costs are high and rising, to establish priorities
for resource planning and preventive policy.
https://doi.org/10.1016/j.jhealeco.2020.102356
0167-6296/© 2020 The Authors. Published by Elsevier B.V. This is  an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
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Some recent studies have used administrative data from
Spain, the UK and the Netherlands (Brilleman et al., 2014;
Carreras et al., 2018; De Meijer et al., 2011; Howdon and
Rice, 2018) to examine the “red herring” thesis (Zweifel
et al., 1999). This suggests that extrapolation of simple
age-health expenditure curves may  not yield an accu-
rate picture of current and future healthcare expenditures,
which are primarily driven by  proximity to death rather
than age itself, with proximity to death in  turn driven by
health and disability status. In a  similar context, Dalgaard
and Strulik (2014),  drawing on research in biology and
medicine to develop an economic model of aging, argued
that age of death is  determined by optimal health invest-
ments and is relevant to biological aging; chronological
aging and death are inevitable but individuals typically
invest in their health, which slows down aging and pro-
longs life.
However, proximity to  death is unobserved prior to
death and therefore of no practical use for projecting health
care expenditure for the needs of health policy. The devel-
opment of forward-looking policy to  control utilisation
of healthcare services and the subsequent costs cannot
be done solely on the basis of records accumulated by
healthcare systems, since those records do  not contain
information about the full range of personal and socioe-
conomic characteristics that may  be required to  account
for confounding effects and do not  have adequate cover-
age of individuals with latent health conditions that have
not yet reached the stage of diagnosis. Analysis aiming to
characterise individuals at risk of generating an increased
burden on the healthcare system and identify potential cost
savings requires data from the general population. Most
relevant existing studies (Brilleman et al., 2014; Carreras
et al., 2018; De Meijer et al., 2011; Howdon and Rice,
2018), although emphasising the importance of the current
morbidity profile of the population for current healthcare
spending, have not  been able to identify individuals within
the ‘apparently healthy’ population, who are nevertheless
at risk of high future rates of healthcare utilisation and
cost. The ability to do this would allow detailed targeting of
health interventions, with the prospect of significant cost
savings. A cumulative biological measure of wear and tear
on the body may  be particularly valuable as a  proxy for
future health risks.
The potential scope for prevention strategies to reduce
health risks and contain healthcare costs has been central
to health policy debates worldwide (Cohen et al., 2008) but
the evidence for their effectiveness so far is  mixed (Russell,
2009). Chernew and Newhouse (2011) argued that bet-
ter targeting of preventative health services to  high-risk
groups is needed to ensure substantial cost savings for pre-
vention strategies, otherwise potential cost savings tend to
be offset by the high cost of unnecessary additional ser-
vices offered to those with no need. This argues for more
research characterising at-risk population groups – espe-
cially those not currently visible to the healthcare system
– to target potential interventions effectively.
Using data from the UK Household Panel Study (UKHLS,
also known as Understanding Society),  the key feature of our
empirical modelling is the use of biomarkers to  predict sub-
sequent healthcare utilisation. UKHLS collects information
on utilisation counts for the numbers of general practi-
tioner (GP) and outpatient/day-patient (OP) consultations,
and the number of days spent as a hospital inpatient (IP)
within the preceding twelve months. Financial costs pro-
vide a  natural metric for combining these different aspects
of resource utilisation into an overall measure of the burden
on the public healthcare system. We use data combination
techniques to incorporate administrative data for England
on GP, OP and IP utilisation and official reference costs to
estimate the excess public costs generated by those with
elevated biomarkers at baseline. By excluding individuals
who  reported any past or  recently diagnosed long-lasting
health condition, we focus on individuals who appeared,
from a clinical point of view, to be healthy at baseline
and who would not therefore already be  prioritised by the
healthcare system. To the best of our knowledge, our anal-
ysis is  the first of its kind.
Our main contribution is  to show the power of
biomarker data at baseline for predicting future health ser-
vice utilisation and concomitant future costs. Use of a long
(five-year) prediction horizon is important, since public
health initiatives and resource planning are not short-term
processes. The biomarkers we use for prediction are more
objective health measures than conventional self-reported
or self-assessed health (Biomarkers Definitions Working
Group, 2001), and several epidemiological studies have
argued that biomarkers can predict future health and mor-
tality risks even in the case of individuals without history of
ill health (Goldman et al., 2006; Glei et al., 2014; Zethelius
et al., 2008; Wang et al., 2006). Biomarkers may  provide
direct information on pre-disease pathways, in particular
by measuring physiological processes that are below the
individual’s threshold of perception (McDade et al., 2007).
However, these epidemiological studies have not consid-
ered cost implications explicitly and it is  possible that the
implications of health for future social costs and utilisa-
tion of healthcare services are quite different from their
implications for any medical measure of health outcome.
In this study, we use a measure of cumulative biological risk
factors, often called allostatic load, which is an index com-
bining biomarkers relevant to different biological systems,
to give an overall assessment of physical health (Davillas
and Pudney, 2017; Howard and Sparks, 2016; Seeman
et al., 2004). The objective nature of biomarkers is  also
important for the design of targeted interventions; unlike
self-assessed and self-reported health measures, biomark-
ers cannot normally be manipulated to  achieve a desired
outcome of the screening process and, thus, they prevent
‘gaming’ of the screening process.
We  develop a  data combination method to incorporate
administrative data on caseload composition and unit costs
in circumstances where administrative data matching at
the level of the survey respondent is  not feasible. Com-
prehensive individual-level administrative healthcare data
are non-existent in many countries and, even where they
do exist, there are legal and ethical data security difficul-
ties that typically prevent matching to suitable longitudinal
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surveys.1 A further difficulty is  that individual-level match-
ing of survey data and administrative records normally
requires informed consent, generating a possible source of
bias (Jäckle et al., 2018; Riley, 2009). In our application, we
attach average unit costs to GP and OP consultation counts,
but use a more sophisticated data combination method for
assigning expected costs to the predictions of the IP util-
isation model, using individual-level survey information
(on age, gender and duration of hospital stays) combined
with administrative data aggregated within broad treat-
ment/demographic patient groups. In applying the data
combination method, we  overcome some difficulties in the
survey observation of healthcare utilisation, which yields
count variables with highly skewed distributions featuring
an excess mass of zero observations (Van Doorslaer et al.,
2004) and counts observed within intervals rather than
as exact figures. We  use a  zero-inflated interval-observed
negative binomial specification, tailored to the form of the
UKHLS data, together with appropriate prediction and sim-
ulation methods for conducting post-estimation analysis.2
It is beyond the scope of this paper to  assess the cost-
effectiveness of any particular screening or  prevention
strategies, but our results have potential implications for
health policy in the UK and beyond. They can be used to
indicate priority areas for interventions (such as screening
programmes and health education initiatives) to control
future treatment costs among individuals who have  not
yet reached the stage of diagnosis. Our analysis provides
general evidence on the pattern of risk of future excess
healthcare costs that is  relevant to the many countries with
healthcare systems similar to the UK (i.e.,  mostly publicly
funded). These results contribute to the policy debate on
the effectiveness of prevention strategies (WHO, 2018),
and suggest that targeting interventions to reduce future
costs may  require more regular collection of biomarkers
at a wider population level than is  usual at present. For
example, the NHS England Health Check offers only quin-
quennial check-ups, including blood tests (Schulein et al.,
2017), to the 40–74 age group, and take-up (around 20%)
is low. However, similar health checks in  Japan are suc-
cessfully offered annually to  full-time employees and the
40–74 age group (OECD, 2019,  chapter 3). Of course, imple-
menting a high-frequency, universal check-up programme
is costly but it may  be  cost-effective if  substantial future
healthcare costs come from the apparently healthy part of
the population. This is related to the prevention paradox of
1 For example, in the  USA, relevant administrative data are typically
based on claims for a selection of insurance providers and do not usually
represent total costs given co-payments (Riley, 2009) and, although the
Medical Expenditure Panel Survey contains data on health care costs, it
lacks objective health measures and baseline health status, including pre-
symptomatic and pre-diagnosed conditions. The UK has no national-scale,
individual-level administrative datasets on GP and community health ser-
vice delivery; hospital episode statistics data have been  linked to  the
Millennium Cohort Study but that is  limited to a  single birth cohort of
pre-mature individuals.
2 In these circumstances, some researchers have either used non-
discrete interval regression models (Brown et al., 2015)  or have sacrificed
information by transforming outcomes into binary variables (Allin et al.,
2011). There have been few applications of the more natural grouped
count data models (but see Fu et al. (2018) for a  Poisson-based example).
the epidemiology literature (Attwood et al., 2016), where
the majority of cases of a  disease may  come from people
at moderate risk of that disease, and only a minority from
people at high risk of the disease.
Our results are  also relevant to the design of capitation
fee systems. Beyond the UK, capitation payment schemes
are used in several European countries, New Zealand and
Canada (Brilleman et al., 2014; Chambers, 1998; Sibley and
Glazier, 2012; Shepherd, 2017), where they are used to
pay providers prospectively for the treatment of patients
to whom they are  contracted to provide healthcare. There
is a  need to  tailor capitation payments closely to expected
future healthcare costs to  reduce incentives for providers
to engage in  “cream-skimming” behaviour. Currently, most
capitation payments are not based on patient-level data,
apart from age and gender, neglecting other potentially
important patient-level characteristics (Brilleman et al.,
2014).
2. Data: the Understanding Society panel (UKHLS)
The UKHLS is  a longitudinal, nationally representative
study of the UK, designed as a  two-stage stratified random
sample of the general population. We use the Great Britain
(GB) subsample, excluding the Northern Ireland compo-
nent of the UKHLS which does not provide biomarker
data. As part of wave 2 (2010–2011), nurse-measured and
non-fasted blood-based biomarkers were collected, giving
a potential pool of 6337 survey respondents with valid
data on all the nurse-collected and blood-based biomarkers
used in our analysis. From those, 4759 individuals had non-
missing data on socioeconomic status and demographic
covariates at baseline (wave 2) and were successfully fol-
lowed up at wave 7,  when healthcare utilisation measures
are collected. Our focus is  on individuals who  appeared
(from the viewpoint of clinical diagnosis) to be healthy at
baseline, so we  further excluded from our analysis those
who reported any past diagnosis of a long-lasting health
condition (asthma, chronic bronchitis, congestive heart
failure, coronary heart disease, heart attack or myocar-
dial  infarction, stroke, cancer or malignancy, diabetes, high
blood pressure, arthritis and liver condition), or  a  hospi-
tal inpatient stay with a newly diagnosed health condition.
This allows us to follow a set of 2314 respondents in appar-
ently good health at baseline, to a  horizon up to five years
later.
2.1. A multi-system measure of health risks at baseline
Allostatic load was  developed as a  measure of biological
risk arising from the cumulated effects of chronic expo-
sure to physical, psychosocial and environmental stressors
that may  lead to physiological dysregulation and elevated
risk of chronic conditions such as cardiovascular disease,
impaired lung and liver functioning (Howard and Sparks,
2016; Seeman et al., 2004). Allostatic load is a  multisys-
tem risk score, sensitive to morbidities that may  be yet
undiagnosed (Geronimus et al., 2006; Turner et al., 2016).
It captures chronic physiological responses and dysregu-
lations relevant to long-term chronic morbidity burdens,
rather than acute infections. Thus the predictive power
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of our allostatic load measure relates more to  healthcare
demands arising from these chronic physical conditions,
rather than those linked to  transient infections, accidental
injury, mental ill-health, etc.
A large set of physical measurements and blood-based
biomarkers, spanning multiple dimensions of health, were
collected by trained nurses at UKHLS wave 2.  Our index
combines markers for adiposity, blood pressure, heart rate,
lung function, inflammation, blood sugar levels, cholesterol
levels, liver function and steroid hormone.3
We use waist-to-height ratio to measure adiposity and
resting heart rate (HR), systolic blood pressure (SBP) and
high-density lipoprotein cholesterol (HDL) to measure car-
diovascular health.4 Lung function is measured using a
spirometer as forced vital capacity (FVC), the total amount
of air forcibly blown out after a  full inspiration; higher
FVC values indicate better lung functioning. C-reactive pro-
tein (CRP) is our inflammatory biomarker, which rises as
part of the immune response to  infection and is associated
with general chronic or systemic inflammation (Emerging
Risk Factors Collaboration, 2010).5 Glycated haemoglobin
(HbA1c) is our blood sugar biomarker, and is a  vali-
dated diagnostic test for diabetes. Albumin is used to
proxy liver functioning, with low albumin levels suggesting
impaired liver function. We also use dihydroepiandros-
terone sulphate (DHEAS), a  steroid hormone in the body,
representing one of the primary mechanisms through
which psychosocial stressors may  affect health, with low
levels associated with cardiovascular risk and all-cause
mortality (Ohlsson et al., 2010). We calculated a composite
risk score measure to proxy allostatic load after convert-
ing HDL, Albumin and DHEAS to negative values to reflect
ill-health rather than good health, and then transforming
each of the nine biomarkers into a  z-score and summing to
produce the composite measure. The index is then scaled
so that a 1-unit increase in allostatic load corresponds to
an increase of one standard deviation.6
To illustrate the magnitudes involved, consider a
healthy woman with waist 79 cm and average height 162
cm, normal systolic blood pressure of 105 mmHg, heart rate
70 bpm, an average HDL cholesterol level of 1.6 mmol/L,
and average values for other biomarkers. If we compare
her with a less healthy woman with waist 88, systolic
blood pressure 140, heart rate 90 and low HDL cholesterol
3 Some authors include cortisol, in addition to the stress-related hor-
mone  dihydroepiandrosterone sulphate (DHEAS), to capture primary
responses to stress. However, cortisol is excluded here because of time-
of-day and other measurement difficulties in the UKHLS context. Similar
constructions to ours have been used extensively in previous studies
(Davillas and Pudney, 2017; Howard and Sparks, 2016; Vie  et  al., 2014).
4 SBP is the maximum pressure in an artery at the moment when the
heart is pumping blood; it is generally considered more relevant to health
risks  than diastolic blood pressure (Haider et  al., 2003). Low  HDL choles-
terol levels are associated with increased cardiovascular risks, while low
HR and SBP indicate lower risks.
5 We  follow common practice by excluding cases with CRP values over
10mg/L because such values normally reflect acute rather than systemic
inflammatory processes (Pearson et al., 2003).
6 When used singly in econometric models, each of these biomarkers
has a statistically significant coefficient, but their strong intercorrelations
make it  impossible to  estimate robust models involving all  nine  biomark-
ers  jointly as covariates.
1.0, then the difference in allostatic load between the two
women  is  1.5 standard deviations.7
2.2. Health care utilisation measures
Retrospective information was also collected at UKHLS
wave 7, on the numbers of: GP consultations; attendances
at a  hospital or  clinic as an out-patient or day patient
(OP); and hospital in-patient (IP) days in  the 12 months
prior to interview. The GP and OP counts were recorded
in five categories (0, 1-2, 3-5, 6-10, more than 10), whereas
respondents were asked for the exact number of days spent
in a  hospital or clinic as an IP  in the same period. We
excluded women who reported any in-patient days for
childbirth during this period (about 0.5% of our  sample),
so our cost analysis excludes services related to  childbirth.
There are clear demographic differences in utilisation.
Fig. 1 shows gender differences in the distributions of
GP and OP consultations, indicating that women  tend to
seek care from GP or  OP consultations more frequently
than men. GP and OP consultations are also more frequent
among older people (Appendix Figures A1 and A2).
The GP, IP, and OP utilisation counts are retrospec-
tive self-reports of utilisation of health services over the
past year, so they are potentially subject to reporting
errors and possibly biases in long-term recall (Bound et al.,
2001). A fundamental difficulty in assessing the prevalence
and nature of survey errors is the absence of an accu-
rate external measure to  validate the survey responses.8
Matched individual-level data on health service utilisa-
tion are not available to us, but  we  can compare the full
wave 7 UKHLS data with external sources of information
(Hobbs et al., 2016; ISD Scotland, 2017; NHS Digital, 2017;
NHS Improvement, 2017). Appendix Tables A1 and A2  give
comparisons of GP and OP consultation data for England
and Scotland and IP days for England only. These compar-
isons are not straightforward, since the UKHLS GP and OP
data are interpolated, there are minor differences in timing,
and the administrative data relate to the whole popula-
tion whereas the UKHLS is  a  sample from the household
population, subject to  variations in response rates across
population groups.9
Overall, we  find that the administrative GP consultation
rates for England and Scotland are reasonably close to mean
counts interpolated10 from the UKHLS interval data (Table
A1). There is some evidence of moderate under-reporting in
the UKHLS, with discrepancies larger for women  than men,
for older than younger respondents and for the English
7 The equivalent comparison for men  of average height 175cm would
involve waist measurements of 93cm and 102.
8 See Meyer and Mittag (2019) for the use of validation data in the
context  of income.
9 The comparisons presented in the appendix use unweighted UKHLS
data.  Since the  UKHLS response weights are built up sequentially over
waves, missing data causes progressive loss of information and, by wave
7  almost a quarter of individuals have zero weights. If we use the offi-
cial  weights, results are  not changed in any important way from those
presented in Tables A1 and A2.
10 Interpolation is  done here by fitting negative binomial distributions
(with  zero-inflation where appropriate) to the interval data, then calculat-
ing  the expected value of the count conditional on  the observed interval.
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Fig. 1. Distribution of the numbers of GP and OP consultations in the preceding 12 months by  gender.
rather than Scottish subsample. For OP consultations (Table
A2) we have no demographic breakdown of the adminis-
trative data; the overall mean counts are reasonably close
to the ratio of aggregate consultations to relevant popula-
tion size, for both England and Scotland (UKHLS rates lower
by 4% and 12% respectively). For  IP  utilisation, we only
have administrative data for England. Unlike most of the
comparisons for GP and OP consultations, the UKHLS mean
IP count is larger (by almost 10%) than the corresponding
administrative estimate (Table A2),  but this is  largely due
to definitional differences – an IP  episode completed within
one day is recorded as a  zero-days duration in the HES data,
but would generally be reported by UKHLS respondents as
a one-day episode. When linking costs to durations (Sec-
tion 5) we allow for this by adding 1 to  durations in the
HES data.
These differences should be  borne in  mind when inter-
preting our results, but do not  seem large enough to greatly
distort econometric results. The main cause for concern is
the possible under-reporting of GP consultations by older
women, which would suggest that the large demographic
effects reported in  Tables 2–4 may  be underestimates.
2.3. Costs
Financial cost is the natural metric for distilling the
three categories of resource use into a  single measure of
burden on public healthcare resources. However, this is
not straightforward because the UKHLS interview gives no
details of the types of treatment involved, nor is it possi-
ble to match survey respondents to records of the public
healthcare system.11 Instead, we pursue a data combina-
tion strategy, exploiting average cost data published in
varying detail for the GP, OP and IP  resource classes.12 For
simplicity, we use reference costs and caseload composi-
11 Consents for matching of UKHLS data to hospital episodes administra-
tive data were obtained for a subset of UKHLS respondents, but a usable
matched dataset is not expected to  be available for a  considerable time.
Moreover, such a dataset would not cover GP consultations and would
raise significant issues of non-consent bias.
12 GP, OP and IP costs are only part of the cost picture. The  UKHLS ques-
tions do not cover resources like community nursing, ambulance services,
etc. Moreover published hospital reference costs exclude some activities
such as screening (Department of Health, 2016, section 15).
tion figures from NHS England for the whole of the UKHLS
sample, including the relatively small Scottish and Welsh
subsamples (making up 5% and 2% of the analysis sample
respectively). Robustness checks reported in Section 6 con-
firm that results are not materially affected by restricting
the sample to respondents resident in  England.
GPs are the gatekeepers to  NHS healthcare services but
they are self-employed contractors rather than employees
of the NHS and, consequently, financial data relating to GP
services are not available on the same detailed basis as for
the rest of the NHS. We  use the mean unit cost per con-
sultation estimated by Curtis and Burns (2017) as £  66.20
per consultation, comprising £  37 for GP costs and £  29.20
for associated prescription costs (on a  net ingredient cost
basis).
NHS reference cost data for OP and IP activity in England
give unit costs broken down in great detail by type of treat-
ment and compiled according to standard measurement
conventions (Department of Health, 2016). We use the
national schedules of reference costs (NHS Improvement,
2017), providing data on average unit cost for each ser-
vice submitted by the NHS providers in  2016/17, a  similar
period to that covered by UKHLS wave 7.  For  OP cases, the
average unit cost and aggregate number of attendances
in each treatment category relate to both  outpatient and
day-case visits. After excluding paediatric categories which
are not relevant to  UKHLS adult respondents, maternity
services and categories with fewer than 50 cases in the
year, we are left with 1,355 treatment categories with an
average caseload of 55,704 attendances per category and
a mean (caseload-weighted) unit cost of £ 163.32 per OP
consultation.13
For  IP cases, reference costs relate to episodes of care,
defined as “the time spent under the care  of one consul-
13 Unlike the reference administrative IP  costs data, which are classified
by  duration of hospital stay, the available unit cost data for GP and OP con-
sultations is  not classified by frequency. It is  possible that patients who
experience more complications more frequently may impose a higher GP
and OP  cost at each consultation than the average for those health ser-
vices. Therefore, our analysis may  under-predict GP and OP costs for such
individuals and over-predict them for individuals with low-cost charac-
teristics. If so, our estimates would give a  lower bound for the gradient
of  future costs with respect to baseline health and other characteristics. If
this  bias exists at all, our focus  on the population group who are apparently
disease-free at baseline is  likely to  moderate its  extent.
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tant”, are available as average unit cost by groups of patient
events that have been judged to consume a  similar level
of resource, known as Healthcare Resource Groups (HRG),
along with the aggregate number of HRG episodes (NHS
Improvement, 2017). Elective and non-elective IP treat-
ment are separated in the official activity and cost data, and
we treat them as distinct treatment types. Treatment cate-
gories are further separated into elective (E), non-elective
long stay (NEL) and non-elective short stay defined as 2
days or less (NES). E and NEL episodes are further split to
allow for excess bed days: health providers are required
to provide per diem costs for the part of longer admissions
that go beyond a ‘trim point’ set for each HRG. In  our analy-
sis, we treat E, NEL and NES episodes as separate categories
within each HRG, exploiting the fact that caseload, unit cost
and mean length of stay (but not other episode character-
istics) are broken down by  type of episode (NHS Digital,
2017; NHS Improvement, 2017). After excluding irrelevant
and negligible categories and those with missing or  invalid
unit cost or mean stay data, we  are left with 3827 IP  cat-
egories, with a  (caseload-weighted) mean stay length of
3.5 days, and a  mean total of case-days of 9184 per cate-
gory. The overall mean daily unit cost defined as the ratio
of aggregate cost to aggregate number of days IP treatment
is £  542 per day. It should be borne in  mind that these
figures relate to all adult in-patients (thus excluding non-
patients with zero costs), whereas our  analysis of UKHLS
survey data is concerned with average costs for the popu-
lation of people with no diagnosed conditions at baseline,
who are likely to have lower (and possibly zero) rates of
healthcare utilisation than the average patient. Thus, our
predicted costs are expected to be smaller than simple
averages estimated from administrative data on patients
as a whole. Descriptive statistics of the variables used in
our analysis are presented in Table A3 of the Appendix.
3. Grouped count data models of healthcare
utilisation
Let Yi ≥ 0 be the ith observation on a  dependent variable
(the GP, OP or IP  utilisation count), which takes non-
negative integer values, and X i a  vector containing the
explanatory covariates. We  allow for the possibility of zero-
inflation: a or mixture process, where some individuals
have a degenerate zero count with probability 1, while oth-
ers have a count drawn from a standard distribution. The
probability of a  degenerate zero is specified as probit14 :
Pr(degenerate0|X i) =  (X i1) (1)
where X i1 is  a subvector of X i.
The distribution of Y among the non-degenerate popu-
lation is g(y|X i2), where X i2 is another subvector of X i.  The
mixture distribution of Y is:
f (y|X i) =
{
(X i1) +  (1 − (X i1))g(0|X i2) if y =  0
(1 −  (X i1))g(y|X i2) if y > 0
(2)
14 We  also estimated logit specifications which gave almost identical
estimates.
Our  observations are not necessarily on Yi itself but
rather an interval within which Yi lies. Consequently, we
have a  pair of observed dependent variables, [Li, Ui] with
the property that Li ≤ Yi ≤ Ui.  For the GP and OP consul-
tation counts, the observable limit pairs are in the set
{(0, 0),  (1,  2),  (3,  5),  (6,  10), (11, ∞)}; for the IP  count we
have exact observation, so Li =  Yi = Ui. The likelihood for
individual i is  the conditional probability of observing the
event Li ≤ Yi ≤  Ui:
Pr(Li ≤ Yi ≤  Ui|X i) =
Ui∑
y=Li
f (y|X i) (3)
The model is completed by specifying a  parameterised
functional form for the non-degenerate component dis-
tribution g(.|X i). We  initially considered three alternative
base models, binomial, Poisson and negative binomial (NB).
The NB specification gave by far the best fit in every
case (Pudney, 2019). It  is derivable as a  Poisson(i)-
gamma
(
˛−1, ˛
)
mixture, where i =  e
X i2ˇ and ln  ˛ is
treated as an unrestricted constant parameter. This gives
a distribution for y with mean i and variance 1 + ˛i.
15
The ML  estimator is  implemented using a  Stata command
intcount (Pudney, 2019).16
4.  Parameter estimates
The explanatory covariates X used in our healthcare
utilisation model represent individual characteristics that
have been shown to  affect health outcomes directly or
indirectly (Davillas and Pudney, 2020; Carrieri and Jones,
2017; Van Doorslaer et al., 2004). They were collected as
part of the UKHLS wave 2 main survey, along with our
biomarker measures. We use two indicators of socioe-
conomic status. Educational attainment is represented
as a  3-category classification: degree-equivalent (refer-
ence category), intermediate, and no/basic qualification.
Household income is the sum of the gross incomes of
all household members but, to avoid spurious correlation
arising from the fact that disability resulting from ill-
health creates eligibility for disability benefits (Morciano
et al., 2015), income from those sources is  excluded.
We  allow for differences in  household composition by
equivalising household income using the modified OECD
equivalence scale before using a  log transformation to
allow for the concavity of the health-income association.
A flexible quadratic function of age and gender is  used
to capture demographic differences. Age is measured in
decades from an origin of 50 years, to  reduce its scale and
the correlation between the linear and quadratic term, to
improve numerical conditioning of the likelihood function.
The transformation of age has no effect on the predic-
15 In the  terminology of Cameron and Trivedi (2013), this is  the  NB2
parameterisation of the regression model. Interval versions of the Poisson
model (Dickman et al., 2004) and its zero-inflated version (Fu et al., 2018)
have  been used before, but we  are  not aware of any previous application
of  a  zero-inflated negative binomial model under interval observation.
16 This  is  a quite standard application of maximum likelihood, but see
Fu et al. (2018) for a  detailed discussion of the asymptotic properties in
the  more special Poisson case.
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tions nor the coefficient and standard error of the quadratic
coefficient. Finally, we also allow for differences between
the three nations of Great Britain (England as the refer-
ence category and Scotland and Wales), since NHS policy
is determined on a national basis.17 The demographic and
socioeconomic covariates are included in the healthcare
utilisation models to  allow us to assess the predictive
power of allostatic load net of the potential confound-
ing effect of individuals’ demographic characteristics and
socioeconomic status. They may  proxy a  wide range of
socioeconomic factors and, thus, do  not necessarily have
a  simple direct causal interpretation.
In  implementing the NB models, we embed an impor-
tant feature of the healthcare system in the UK. GPs
normally act as gatekeepers to  the hospital system, so OP or
IP episodes are mostly preceded by  GP consultations (Van
Doorslaer et al., 2004; Brilleman et al., 2014). For that rea-
son, we model OP and IP utilisation counts conditional on
the number of GP consultations, with X extended to  include
categorical indicators of the number of GP consultations.
Parameter estimates for our preferred models are shown
in Table 1 (columns 2, 4 and 6). Marginal OP and IP mod-
els, estimated without conditioning on the GP consultation
count, are also shown for comparison (columns 3 and 5). For
the OP and IP counts, the best-fitting model involves zero-
inflation, distinguishing between individuals with zero and
non-zero GP consultation counts. The estimated impact of a
zero GP count on the OP and IP  counts is almost completely
sharp, with large negative intercept and large positive coef-
ficient. That implies negligible zero-inflation for the OP and
IP counts if the GP count is positive, and large probabilities
of a degenerate zero (0.69 for the OP count and 0.98 for the
IP count) if the GP count is  zero.18
Table 1 shows a  significant predictive role of allostatic
load for GP consultations, implying an expected increase
of e0.21 − 1 = 23% in GP  consultations five years after a  one
standard deviation increase in allostatic load. In models for
OP and IP that condition on the GP count, there is  no further
statistically significant direct impact of allostatic load, so
the effect of allostatic load is  primarily channeled through
17 We  used initially a larger set of covariates than that shown in
Table 1, including additionally urban/rural area type, marital status, hous-
ing  tenure and household size. We  dropped covariates only where their
coefficients were statistically insignificant at  the 10% level in all mod-
els, resulting in the smaller set of covariates listed in Table 1. To curtail
pre-test  bias, we  retained the remaining covariates in all models, irrespec-
tive of statistical significance in particular models. Inclusion of smoking
and physical activity produced no significant effects in any model after
accounting for allostatic load, indicating that information on unhealthy
lifestyles at baseline has no additional predictive power for subsequent
health care utilisation beyond what can  be achieved using biomarkers.
18 In practice the gatekeeper role  of GPs is not  completely sharp, since
GP consultations leading to an OP consultation or IP episode may not  fall
in  the same 12-month recall period; also some emergency IP  cases may
reach  hospital without GP involvement. Consequently we have chosen to
leave the model fully parameterised rather than imposing a zero probabil-
ity  of zero-inflation when the GP count is zero. For zero-inflated models of
the  GP count, the ML  optimisation always led to corner solutions where
the probability of a degenerate zero count was essentially zero.  Demo-
graphic  and socioeconomic covariates were not significantly significant
in  the zero-inflation probit component of the conditional models for OP
and IP.
the increased engagement with primary healthcare. The
marginal models of OP and IP that do not condition on  the
GP count have highly significant coefficients of 0.129 and
0.555, implying total five-year impacts of a  standard devi-
ation increase in allostatic load as 14% for OP consultations
and, much higher, at 74% for IP days. The statistical depen-
dence between the GP count and the OP and IP counts is
confirmed by the large significant coefficients for the GP
variables in  the conditional OP and IP  models, and the much
higher AIC and BIC statistics for the models that do not
condition on GP visits.
Specifying higher order polynomials of allostatic load
(second or third order) revealed no significant nonlinearity
in  any of our model specifications (P-values between 0.205
and 0.985). To determine whether the predictive role of
allostatic load varies by age and gender, we tested the rele-
vant interaction terms in all model specifications for GP, OP
and IP  utilisation counts. There were no significant differ-
ences: P-values for the interactions of allostatic load with
gender range between 0.105 and 0.830 across the different
models; those for age interactions range between 0.155 and
0.699.19
We  now consider the sub-sample of individuals with
elevated levels of allostatic load at baseline (defined as at
least one standard deviation above the mean), and examine
the expected savings in  future healthcare resource utilisa-
tion and cost generated by that group, which would result
under a counterfactual where each had their allostatic load
lowered by one standard deviation. Since we  are interested
in  the effect of variations in  allostatic load on the aggre-
gate burden of treatment within this part of the population,
it is  appropriate to  examine the mean of the counterfac-
tual effect over all members of the group, rather than the
effect calculated for an ‘average’ individual to represent
the group.20 To do  this, we  use the following sequential
Monte Carlo simulation, conditional on the observed base-
line covariates, where r  = 1. . .R indexes pseudo-random
replication sequences.21
(i) For each member i of the group with elevated allo-
static load at baseline, construct counterfactual covariate
vectors X∗i identical to  the observed X i,  but with the allo-
static load variable reduced by 1 standard deviation unit
for each individual.
19 As a further sensitivity check, we  also re-estimated our preferred util-
isation models using age-gender dummies instead of age polynomials;
we still failed to reject the null hypothesis of linearity in allostatic load
(P-values ranging from 0.142 to 0.893).
20 Of course, this  is a  quantitative summary of the importance of allo-
static load as an indicator of the risk of future excess costs, not a  policy
simulation. Any feasible public health intervention would have a  much
more  complex outcome than an immediate one standard deviation reduc-
tion  in allostatic load. Note also that, unlike a marginal effect for an
‘average individual’, these average effects are not generally symmetric
across groups – for example, the effect of transforming those observed
to  be male into counterfactual females is  not the negative of the effect of
transforming sampled females into counterfactual males.
21 It is  possible to construct confidence intervals for simulated resource
utilisation and cost, using bootstrap resampling. This requires repetition of
the model estimation and utilisation/cost simulation and is very intensive
in computer time. For this reason, we report confidence intervals only for
the key estimates of the effects of allostatic load in Tables 2  and 4 .
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Table 1
Estimated parameters for grouped negative binomial models of GP, OP and IP  utilisation: baseline demographic, socioeconomic and health state coefficients.
OP  model IP  model
GP Marginal Conditional Marginal Conditional
Parameter (1)  (2) (3) (4) (5)
Allostatic load 0.210*** 0.129**  −0.030 0.555*** 0.219
(0.036) (0.053) (0.055) (0.162) (0.175)
Age§ −0.053* 0.033 0.068 0.241 0.177
(0.030) (0.046) (0.045) (0.154) (0.137)
Age2§ 0.017 0.018 0.002 −0.024 −0.051
(0.016) (0.026) (0.026) (0.081) (0.072)
Male −0.198*** −0.327*** −0.319*** −0.285 −0.493
(0.076) (0.121) (0.110) (0.397) (0.370)
Age  × male§ 0.146*** 0.187*** 0.119*  −0.367* −0.165
(0.042) (0.069) (0.067) (0.209) (0.201)
Age2× male§ −0.025 0.024 0.061*  0.182 0.247**
(0.025) (0.038) (0.037) (0.117) (0.111)
No  qualifications† 0.092 0.033 −0.016 0.744 1.481**
(0.092) (0.142) (0.137) (0.566) (0.718)
Intermediate qualifications† 0.016 0.104 0.112 0.691**  0.745**
(0.065) (0.103) (0.096) (0.321) (0.290)
ln(income) −0.140*** −0.106* −0.002 −0.209 0.101
(0.045) (0.062) (0.059) (0.237) (0.206)
Walesa 0.555*** 0.140 −0.365 −0.061 −1.062*
(0.192) (0.332) (0.249) (0.694) (0.590)
Scotlanda −0.018 −0.246 −0.311 0.278 −0.405
(0.135) (0.231) (0.198) (0.776) (0.680)
Intercept 1.793*** 1.001**  0.165 −0.270 −1.573
(0.351) (0.483) (0.481) (1.883) (1.670)
Impact of conditioning on GP consultation count (reference level = 0)
1-2  −0.237 −1.384*
(0.206) (0.794)
3-5  0.534*** −1.248
(0.206) (0.817)
6-10  0.952*** −0.203
(0.214) (0.860)
more  than 10 1.977*** 1.640**
(0.270) (0.832)
ln(˛) 0.012 1.099*** 0.489*** 3.895*** 3.307***
(0.056) (0.058) (0.075) (0.121) (0.150)
Zero-inflation parameters
zero GP consultation count 16.68*** 14.97***
(0.322) (0.722)
intercept  −16.17*** −12.86***
(0.233) (0.558)
AIC 6067.9 4913.3 4480.0 1514.5 1445.4
BIC  6142.6 4988.0 4589.2 1589.2 1554.6
§ Age measured in decades from an origin of 50. Standard errors in parentheses. Sample size  N  = 2314.
† Reference categories: degree-level education.
a England.
* Statistical significance: 10%.
** Statistical significance: 5%.
*** Statistical significance: 1%.
(ii)  At each replication r, draw a  pair of pseudo-
random counts YGP
ir
,  YGP∗
ir
from the conditional distributions
Pr(YGP
i
|X i)  and Pr(Y
GP∗
i
|X∗i ), derived from the fitted model
for GP consultations (column (1), Table 1). The same under-
lying set of pseudo-random numbers is  used to  generate
both YGP
ir
and YGP∗
ir
.
(iii) At each replication r, use YGP
ir
to construct a vector Z ir
containing the five additional dummy  variables represent-
ing GP utilisation which appear in the conditional OP and
IP models (columns (3) and (5) of Table 1), and construct
an extended covariate vector X†
ir
= (X i, Z ir). Then evalu-
ate Pr(YOP
i
|X†
ir
) and Pr(Y IP
i
|X†
ir
) for each individual, using
the fitted conditional models for OP and IP consultation
counts, and draw pseudo-random YOP
ir
and Y IP
ir
from those
distributions.
(iv) Repeat step (iii), substituting the counterfactual
X∗i , Y
GP∗
ir
for X i, Y
GP
ir
but re-using the same underlying
pseudo-random numbers, to generate counterfactual out-
comes YOP∗
ir
, Y IP∗
ir
.
(v) Compute any means and probabilities of posi-
tive counts for YGP, YOP, Y IP over all individuals i in  the
elevated-allostatic load group and all R  replications. For
each utilisation count Y , average marginal effects are
expressed as % differences between base and counterfac-
tual outcomes. For mean counts, they are computed as
100 [
∑
i
∑
r
(Y∗
ir
− Yir)]/
∑
i
∑
r
Yir ,  while the %  difference at
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the extensive margin is 100 [
∑
i
∑
r
(1(Y∗
ir
> 0) −  1(Yir >
0))]/
∑
i
∑
r
1(Yir > 0) and 1(.) is the indicator function.
The results are shown in Table 2. Confidence intervals
are wider for the OP and IP impacts, because OP and IP
consultations are  relatively uncommon and because the
estimates relate to averages over a small subsample of indi-
viduals with allostatic load at least one standard deviation
above mean at baseline.22 Allostatic load proves to  be a  very
strong predictor of future healthcare demand, suggesting
potential for a substantial reduction in  resource usage if
effective interventions could be targeted on those with
high allostatic load. Most of the effect is  at the intensive
rather than extensive margin, with the proportion of indi-
viduals calling on GP, OP and IP  resources reduced much
less proportionately than is the mean consultation count.
A  1 reduction among the group with high allostatic load
is predicted to reduce GP and OP consultations by  19% and
12% respectively. Results for the more costly IP  resource are
stronger still, with a  1  reduction in  allostatic load reducing
expected future resource usage by  over 40%. Allostatic load
is  a particularly effective predictor for relatively serious
conditions requiring hospital stays.
5. Costs
Our procedure for inferring costs necessarily differs
between the GP, OP and IP resource types because of dif-
ferences in the detail available from NHS reference cost
statistics. In Britain, GPs are independent contractors to
the NHS and there is consequently less detailed administra-
tive data relating to the treatment profile of their caseloads
and the corresponding costs than there is  for hospital treat-
ments. For GP consultations we have used a  single average
unit cost figure of cGP = £66.20 per consultation (Curtis and
Burns, 2017). To exploit this unit cost figure, we assume
that the unobserved true individual-specific average cost
of a GP consultation may  vary between individuals, but is
uncorrelated with the number of consultations, conditional
on personal characteristics, implying that the conditional
expected cost incurred for individual i is:
E
(
CGPi |X
GP
i
)
=  cGPE
(
YGPi |X
GP
i
)
(4)
For  OP cases in each treatment category j, there is
a  unit cost cOP(j) and aggregate number of treatment
episodes nOP(j),  from which category proportions can be
constructed as OP(j) = nOP(j)/
∑
nOP . By the same reason-
ing as before, we arrive at a  conclusion that E
(
COP
i
|XOPir
)
=
cOPE
(
YOP
i
|XOPi
)
, where cOP =
∑
j
OP(j)cOP(j) and XOPir is the
22 Our use of 90% confidence intervals is  motivated by  a belief that
the relevant alternative hypothesis is  1-sided rather than 2-sided – it
is  implausible to suggest that worsening health reduces the  expected
healthcare burden. Thus the lower limit of the 90% confidence interval
can be interpreted either as part of a  2-sided 90% interval, or more appro-
priately as a 95% 1-sided confidence limit on the magnitude of the effect.
The bootstrap calculation is burdensome because it involves simulation
within simulation. We  attempted 300 bootstrap replications; 23 were lost
due  to non-convergence of one or more of the re-estimated models. We
have not attempted to  modify specifications or explore alternative starting
values  for the ML  optimisation in those 23  cases.
covariate vector in the OP consultation model, constructed
at replication r using YGP
ir
.
Table 3 summarises the cost simulations for each of nine
hypothetical variations: a 1 reduction in  allostatic load for
all those who are at least 1  above the mean; an increase in
age of 10 years for all members of each of five baseline age
groups; changing gender for the two gender groups in  turn;
increasing educational attainment by one category for the
unqualified and the intermediate group; and a universal
10% increase in equivalised income. This analysis allows us
to  interpret the results by comparing the predicted impact
of a  reduced allostatic load with demographic and socioe-
conomic differences in healthcare costs.
The expected GP costs in Table 3 are  particularly high for
the group with elevated allostatic load compared to  all the
comparator demographic and socioeconomic groups. For
example, the mean base  cost for those with high allostatic
load is  about £ 207, exceeding even the GP costs incurred
for the over-75 age group. A 1 reduction in baseline allo-
static load for those with elevated values would reduce GP
costs by almost one-fifth, holding other characteristics con-
stant. This almost four times larger in  magnitude than the
proportional increase in the GP costs from an additional 10
years of age among the oldest group, and is only exceeded
by the proportional difference in mean GP costs between
men and women.
The mean OP costs in  Table 3 are uniformly higher than
GP costs across the set of illustrative baseline population
groups. Predicted mean OP costs for the group with ele-
vated allostatic load (£ 295) exceed those of every other
group except for the over-75s (£ 420). For the former group,
a  1 reduction in allostatic load reduces predicted mean
OP costs by over 12%, which is larger in  magnitude than
the proportionate impacts of differences in education and
income, but smaller than the effects of gender or  of ageing
by ten years among the over-45 population.
For IP cases, we  have much richer cost and caseload
information (Section 2.3). For  each treatment category, we
observe caseload broken down by age group and (sep-
arately) by gender. We also observe average unit cost
and upper and lower quartiles of unit cost for normal
length episodes. Treatment categories are further sepa-
rated into elective (E), non-elective long stay (NEL) and
non-elective short stay defined as 2 days or  less (NES). We
treat these types as separate categories, exploiting the fact
that caseload, unit cost and mean length of stay (but not
other episode characteristics) are  broken down by type of
episode.
We  follow NHS reporting practices which give episode
unit costs for durations within a  specified limit (“trim
point”) and a  lower unit cost for “excess stays” – the part of
any episode beyond the trim point. So, for the jth treatment
category, the episode-specific cost function is:
cj(Y) =  1jmin(Y, Tj)  +  2jmax(0,  Tj − Y) (5)
where Tj is the trim point, 1j is the per diem unit cost for
“inlier” episodes completed within the normal time and 2j
is the per diem unit cost for excess days.
To incorporate the unit cost information, in each repli-
cation of the Monte Carlo simulation outlined in Section
4, we construct an individual-specific probability of each
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Table 2
Estimated effects of a  one standard deviation reduction in allostatic load on  expected future resource utilisation counts among individuals with elevated
allostatic load at baseline.
Service type Mean base
count†
Marginal effect [90%
confidence interval] §
Base proportion
positive†
Marginal effect at extensive
margin‡ [90% confidence
interval]§
GP consultations 3.12 −18.9 0.75 −5.4%
[-27.8%, -15.6%] [-7.9%, -4.4%]
OP  consultations 1.80 −12.4 0.46 −4.9%
[-24.4%, -2.4%] [-9.3%, -1.1%]
IP  days 0.94 −43.5 0.07 −15.4%
[-63.0%, 10.2%] [-44.2%, 4.5%]
† Predicted mean count and probability of positive utilisation averaged over the 359 individuals with allostatic load at  least 1 above mean at baseline
(15.5% sample proportion).
‡ Percentage difference in the proportion with positive utilisation within the high-allostatic load group.
§ Nonparametric bootstrap confidence intervals, with both model estimation and utilisation simulation repeated at  each of 277 bootstrap replications.
Table 3
Personal characteristics and annual GP and OP costs five years later.
GP consultations OP  consultations
Base sample and Mean base %  change Mean base % Change
hypothetical variation cost in cost cost in cost
High allostatic load - 1 £ 207 −18.9† £  295 −12.4†
Age 16–29 + 10 years £ 128 −5.1 £  168 −3.5
Age 30–44 + 10 years £ 133 −2.4 £  173 5.2
Age  45–59 + 10 years £ 140 1.4 £  194 16.8
Age  60-74 + 10 years £ 166 4.1 £  266 37.2
75  and over + 10 years £ 197 5.2 £  420 62.4
Males → female £ 119 26.9 £  171 32.6
Females → male £ 162 −23.2 £  231 −28.5
No  qualifications → intermediate £ 179 −7.4 £  251 7.1
Intermediate → degree £ 141 −1.6 £  208 −11.6
All  incomes + 10% £ 143 −1.3 £  205 −1.0
Sample sizes: high allostatic load: 359; age 16–29: 239; age 30–44: 740; age 45–59: 823; age  60–74: 444; age over 75: 68; males: 1018; females: 1296; no
qualifications: 345; intermediate qualifications: 945; all incomes: 2314.
† Predicted costs are proportional to predicted utilisation for GP and OP  services, so the  %  change in cost is  identical to  the corresponding figure in Table 2.
treatment type, conditional on the simulated treatment
duration and observed characteristics of each individual.
Those probabilities are  used to  calculate the conditional
expected treatment cost, which is then averaged over the
250 Monte Carlo replications. The procedure is necessarily
complex and is set out in detail in  Appendix 2. Table 4 gives
two alternative sets of cost estimates. The first (columns
1 and 2) uses only the simulated IP duration to tailor
treatment type probabilities to individuals; the second
(columns 3 and 4) uses duration, age group and gender
to tailor the treatment probabilities. Perhaps surprisingly,
the additional use of demographic information changes the
simulated costs rather little.
The predictive power of allostatic load is again clear.
The subgroup with allostatic load more than 1 above the
mean are predicted to generate a  mean total cost of just
over £ 320 five years later (compared to a  mean prediction
of approximately £ 175 for the whole sample). If allostatic
load were hypothetically reduced by  1 for each member of
this group, the implication would be a reduction of almost
a quarter in their future IP costs: roughly comparable to ten
years’ ageing in  middle age and early old age.23
23 The estimated % change in cost for the 45–59, 60–74 and over 75 age
groups (16.3%, 28.3% and 52.4% respectively), weighted by group sample
numbers, average to 22%.
The second panel of Table 4 combines the results
for GP, OP and IP costs to give a picture of the overall
influences on total direct treatment costs and confirms
the major influence of allostatic load. Those with ele-
vated biomarkers at baseline are predicted to  generate
a  mean total cost of £  823 five years later. If allostatic
load were hypothetically reduced by one standard devia-
tion for each member of this group, combined future GP,
OP and IP  costs are  predicted to  be reduced by 18%, so
there is  clear scope for an effectively targeted interven-
tion to curtail future healthcare costs significantly. This
projected % reduction in total cost is broadly comparable
with the predicted cost differences stemming from age-
ing (19% weighted average effect of an additional 10 years
for the 45–59, 60–74 and 75+ groups), gender (approxi-
mately 22%) and one category of education (approximately
17%).
6. Limitations and robustness
Our analysis has significant limitations, some of which
are inherent in any research in  this area. Like any survey-
based analysis, estimates are subject to possible distortion
from various types of general and item non-response,
particularly related to the biomarker data used to mea-
sure baseline health objectively. Moreover, any attempt to
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Table  4
Personal characteristics and expected IP  costs and total costs five years later.
Statistical allocation on...
Duration only Duration + age + gender
Mean % change Mean %  change
Base  group and base cost in cost base cost  in cost
hypothetical variation (1) (2) (3) (4)
Conditional mean IP  costs
High allostatic load -  1 £  321 −23.2 £  323 −23.8
[90% confidence interval]§ [−49.2, 7.5]
Age  16–29 + 10 years £  142 −17.4 £  136 −15.9
Age 30–44 + 10 years £  134 2.4 £  125 7.9
Age  45–59 + 10 years £  163 11.7 £  162 16.3
Age  60–74 + 10 years £  243 30.4 £  258 28.3
75  and over + 10  years £  450 55.6 £  442 52.4
Males  → female £  160 10.0 £  163 6.1
Females  → male £  187 −11.3 £  182 −8.2
No  qualifications → intermediate £  354 −37.1 £  358 −35.3
Intermediate → degree £  179 −36.6 £  175 −34.5
All  incomes + 10% £ 175 −0.8 £ 174 −0.1
Conditional mean total (GP+OP+IP) costs
High allostatic load -  1 £  823 −18.2 £  825 −18.5
[90% confidence interval]§ [−28.5, −8.7]
Age 16–29 + 10 years £  438 −8.5 £  432 −7.9
Age 30–44 + 10 years £  439 2.1 £  430 3.6
Age  45–59 + 10 years £  496 10.8 £  495 12.2
Age  60–74 + 10 years £  675 26.6 £  690 25.9
75  and over + 10  years £  1,067 49.0 £ 1,059 47.6
Males  → female £  450 23.1 £  453 21.6
Females  → male £  581 −21.5 £  576 −20.6
No  qualifications → intermediate £  784 −16.2 £  788 −15.5
Intermediate → degree £  529 −17.4 £  524 −16.5
All  incomes + 10% £  523 −1.0 £  522 −0.8
§ Nonparametric bootstrap confidence intervals, with both model estimation and utilisation simulation repeated at  each of 277 bootstrap replications.
attach costs to healthcare utilisation involves accounting
and recording errors inherent in  the available reference
cost data, which are averages across groups of cases
rather than true individual-specific costs and exclude
some cost elements (such as most community health ser-
vices).
Our methodology of statistical cost allocation rests on
assumptions that may  seem strong at first sight, although
we would argue that they are more innocent than they
appear. In estimating IP costs, we  assume an individual’s
reported number of days in the hospital (that is, each
admission) stem from a single episode. It  should be  noted
here that the payment by results reimbursement scheme,
adopted by the NHS since 2004, provides no  financial
incentive for healthcare providers to increase the number
of episodes per admission, aiming to promote both effi-
ciency and the accuracy of the initial diagnosis. According
to NHS statistics, the vast majority of the patient spells
(a  continuous period of time spent as a patient within a
trust, which is equivalent to an admission) have only one
episode, while there is  only a tiny proportion of admis-
sions with three or more episodes (Department of Health,
2012). Note also that the expected total cost over multiple
episodes is the sum of the expected cost of each, so mul-
tiple episodes have no inherent impact on expected total
cost, only indirectly through our  use of duration in  the cal-
culation of individual-specific probabilities of alternative
disease/treatment types.
The outcomes that we study are necessarily limited. We
look at healthcare utilisation five years after the baseline as
a  single snapshot, rather than a  long-term sequence of out-
comes, and we can say nothing directly about the duration
of those impacts on the public healthcare system. Since we
do  not  have biomarker measurement repeated over time,
we do not observe change in biomarkers and can therefore
say nothing definite about the optimal frequency of mea-
surement within a  real-world screening programme. Our
cost analysis is  a  distributional analysis in  the sense that it
assigns cost to the individual whose ill-health generates the
need for treatment. That analysis contributes to our under-
standing of the processes leading to escalating health costs,
but it does not  tell us about the distribution of the financial
burden of those costs across the population, which depends
on the redistributive nature of the tax system used to fund
public healthcare costs.
We carried out sensitivity checks to  determine whether
our results are sensitive to our use of English NHS reference
cost data to the whole sample, which includes individual’s
resident in Wales and Scotland. Restricting the analysis to
English residents (93% of our full sample) gives results that
are practically identical to those for the full GB sample both
in terms of model estimates (Appendix Table A4) and cost
implications (Table A5). We  also assessed sensitivity to the
role of medications by repeating our analysis excluding the
few individuals (4% of the sample) who, at baseline, were
taking medication for high blood pressure, cardiovascular
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conditions, diabetes or respiratory conditions.24 The model
estimates (Table A6) and cost simulation results (Table A5)
are very close to our primary results.
7. Discussion and conclusions
In this paper we  have adopted a forward-looking
approach to explore the predictive power of biomarkers
and other personal characteristics for the utilisation of
health services and associated costs, five years later. To
the best of our knowledge, it is  the first analysis of its
kind. Using data from UKHLS on a  group of individuals
with no history of diagnosed health conditions, we  find
that a biomarker-based approximation to allostatic load
reflecting pre-diagnosed and pre-symptomatic pathways
is a powerful predictor of the future burden of service util-
isation for the primary and hospital healthcare systems.
Combining the prediction models with healthcare cost data
for England, we have quantified the excess healthcare costs
generated by those individuals with elevated biomarkers at
baseline. To achieve this, we developed a  simulation-based
method of assigning administrative cost estimates to the
service utilisation levels predicted by  count data models,
incorporating both duration and demographic characteris-
tics to personalise the assignment in  the case of inpatient
treatment episodes.
Overall, we found that those with elevated biomarkers
are predicted to generate a  mean annual total healthcare
cost (GP, OP consultations and IP  days) of £  823 five years
later. A standard deviation reduction in allostatic load for
each member of this group resulted in  an 18% reduction
in predicted total costs, with the largest impact for hospi-
tal inpatient treatment. These results suggest that there is
clear scope for interventions targeted effectively on those
with elevated biomarkers to reduce future health care costs
significantly – if such interventions can be designed. The
magnitude of the effects of allostatic load on caseloads and
costs is broadly comparable with the substantial estimated
influence we  found for age and education. Although the
main focus of our paper is  not the socioeconomic gradient
in healthcare and costs, our results extend previous evi-
dence of the impact of education on health (Conti et al.,
2010) to healthcare utilisation and costs.
The predictive power of the biomarker-based health
measures gives a possible basis for sophisticated tailor-
ing of preventive interventions. Our findings suggest that
effective targeting reflecting the biological pattern of risk
using biomarker data could identify better the popula-
tion groups with highest potential future healthcare needs
and costs. A measure similar to our allostatic load proxy
could be constructed from information gathered in  screen-
ing check-up programmes, like the NHS England Health
Checks and similar programs in other countries includ-
ing Australia, Germany, the Netherlands and Japan (OECD,
2019; Schülein et al., 2017). Recent technical develop-
ments have expanded the options for obtaining biomarkers
24 These individuals reported taking medication despite having reported
no  such diagnosed conditions. It is  not certain which of the two reports is
erroneous in any given case.
at the population level. As an alternative to conventional
venepuncture, dried blood spot (DBS) sampling (drops
of whole blood collected on filter paper from a simple
finger prick) offers a  minimally invasive method for sam-
pling blood, at a  significantly lower collection cost (Martial
et al., 2016; McDade et al., 2007). Recent evidence allevi-
ates concerns over the validity of DBS-derived biomarkers
(Samuelsson et al., 2015), suggesting that the DBS method
has become an effective way  to implement blood-based
screening tests on a  large scale in practice. We  hope that
technical improvements and evidence of the kind pre-
sented here may  contribute to  the development of these
programmes to improve their cost-effectiveness.
There is a  continuing debate on capitation-based pay-
ments that are currently used to allocate budgets to GPs in
a  number of countries (Brilleman et al., 2014; Chambers,
1998; Sibley and Glazier, 2012; Shepherd, 2017). A poten-
tial policy application of our findings is in  refining the
design of these systems by reorienting the capitation for-
mula to  match more closely patient level morbidity data
and other individual characteristics (Shepherd, 2017). This
offers the prospect of improved allocation of resources and
better health outcomes by reducing incentives for health
providers to  “skim the cream” from the patient population
by selecting patient sub-groups with lower expected future
healthcare costs.
Appendix A. Supplementary Data
Supplementary data associated with this article can be
found, in the online version, at https://doi.org/10.1016/j.
jhealeco.2020.102356.
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